Targeting cysteine-rich angiogenic inducer-61 by antibody immunotherapy suppresses growth and migration of non-small cell lung cancer

Mostrar otras versiones (1)

Non-small cell lung cancer (NSCLC) is the most frequent type of human lung cancer; lung cancer is responsible for the highest rates of cancer-associated mortality in the world. Cysteine-rich angiogenic inducer-61 (CYR-61) has been identified as a tumorigenesis-, development- and metastasis-related g...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xinpeng, Yuan, Naxin, Lin, Lingdan, Yin, Lixia, Qu, Yiqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090314/
https://www.ncbi.nlm.nih.gov/pubmed/30116327
http://dx.doi.org/10.3892/etm.2018.6274

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090314/
https://www.ncbi.nlm.nih.gov/pubmed/30116327
http://dx.doi.org/10.3892/etm.2018.6274

Ejemplares similares